ROFECOXIB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H14O4S
Molecular Weight	314.356
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3

InChI

InChIKey=RZJQGNCSTQAWON-UHFFFAOYSA-N

InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3

HIDE SMILES / InChI

Molecular Formula	C17H14O4S
Molecular Weight	314.356
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf | http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm106290.htm

Rofecoxib is a nonsteroidal anti-inflammatory drug which selectively inhibits COX-2 and subsequent prostaglandin synthesis. The drug was developed by Merk and approved by FDA in 1999 for relief of signs and symptoms of arthritis, acute pain in adults, and painful menstrual cycles under the name Vioxx. Later on Merck voluntarily withdrawn Vioxx from the market due to safety concerns (high risk of heart attack and stroke).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	Inhibitor 8504		0.02 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Hemophilic Arthropathy 1 Sources: https://adisinsight.springer.com/drugs/800050774 https://www.mdedge.com/rheumatology/article/152669/bleeding-disorders/fda-grants-orphan-drug-status-rofecoxib-hemophilic	Primary	Phase II 1147	Unknown Approved Use Unknown
Osteoarthritis 157 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	Palliative	Withdrawn	VIOXX Approved Use For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults. Launch Date 1999
Rheumatoid arthritis 320 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	Palliative	Withdrawn	VIOXX Approved Use For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults. Launch Date 1999
Acute pain 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	Primary	Withdrawn	VIOXX Approved Use For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults. Launch Date 1999
Primary dysmenorrhea 16 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	Primary	Withdrawn	VIOXX Approved Use For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults. Launch Date 1999
Migraine 107 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	Primary	Withdrawn	VIOXX Approved Use For relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis in adults, pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older and who weigh 10 kg (22 lbs) or more, for the management of acute pain in adults, for the treatment of primary dysmenorrhea, for the acute treatment of migraine attacks with or without aura in adults. Launch Date 1999

C_max

Value	Dose	Co-administered	Analyte	Population
321 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ROFECOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
4018 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ROFECOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
17 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ROFECOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
13% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021042s033,021052s024lbl.pdf	25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ROFECOXIB plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
12.5 mg 1 times / day steady, oral Recommended Dose: 12.5 mg, 1 times / day Route: oral Route: steady Dose: 12.5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17664473/	unhealthy, 44-76 years Health Status: unhealthy Age Group: 44-76 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17664473/	Disc. AE: Renal impairment... AEs leading to discontinuation/dose reduction: Renal impairment (grade 1, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/17664473/
50 mg 1 times / day steady, oral Studied dose Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17664473/	unhealthy, 44-76 years Health Status: unhealthy Age Group: 44-76 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17664473/	Sources: https://pubmed.ncbi.nlm.nih.gov/17664473/
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17652651/	unhealthy, 58–71years Health Status: unhealthy Age Group: 58–71years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17652651/	Disc. AE: Cardiac thrombosis... Other AEs: Cardiac thrombosis... AEs leading to discontinuation/dose reduction: Cardiac thrombosis (grade 5, 4 patients) Other AEs: Cardiac thrombosis (16 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/17652651/
25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12495363/	unhealthy, 66.8 years Health Status: unhealthy Age Group: 66.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12495363/	Disc. AE: Dyspepsia, Nausea... AEs leading to discontinuation/dose reduction: Dyspepsia (4.4%) Nausea (2.4%) Dizziness (2.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/12495363/
25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/	Disc. AE: Death... Other AEs: Hemorrhage, Edema... AEs leading to discontinuation/dose reduction: Death (grade 5, 1653 patients) Other AEs: Hemorrhage (3915 patients) Edema (3677 patients) Thrombosis (1917 patients) Embolism (233 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/

AEs

AE	Significance	Dose	Population
Renal impairment	grade 1, 1 patient Disc. AE	12.5 mg 1 times / day steady, oral Recommended Dose: 12.5 mg, 1 times / day Route: oral Route: steady Dose: 12.5 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17664473/	unhealthy, 44-76 years Health Status: unhealthy Age Group: 44-76 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17664473/
Cardiac thrombosis	16 patients	25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17652651/	unhealthy, 58–71years Health Status: unhealthy Age Group: 58–71years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17652651/
Cardiac thrombosis	grade 5, 4 patients Disc. AE	25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17652651/	unhealthy, 58–71years Health Status: unhealthy Age Group: 58–71years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/17652651/
Dizziness	2.1% Disc. AE	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12495363/	unhealthy, 66.8 years Health Status: unhealthy Age Group: 66.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12495363/
Nausea	2.4% Disc. AE	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12495363/	unhealthy, 66.8 years Health Status: unhealthy Age Group: 66.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12495363/
Dyspepsia	4.4% Disc. AE	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/12495363/	unhealthy, 66.8 years Health Status: unhealthy Age Group: 66.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/12495363/
Thrombosis	1917 patients	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/
Embolism	233 patients	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/
Edema	3677 patients	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/
Hemorrhage	3915 patients	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/
Death	grade 5, 1653 patients Disc. AE	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/19453292/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 1079 CYP2E1 1060	UGT1A1 479 UGT1A3 470 UGT1A4 399 UGT1A6 343 UGT1A8 323 UGT1A9 423 UGT2B7 456 UGT2B15 236

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21042lbl.pdf#page=4 Page: 4.0	likely	weak (co-administration study) Comment: A 30% interactions, additional studies would be necessary reduction of the AUC of the CYP3A4 substrate to more completely elucidate the drug interaction midazolam was observed with rofecoxib 25mg profile of rofecoxib and determine the clinical rele- daily. This reduction is most probably due to in- vance of any possible interactions. creased first-pass metabolism through induction of intestinal CYP3A4 by rofecoxib Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21042lbl.pdf#page=4 Page: 4.0
CYP2C9 2497	inhibitor 4027 Sources: https://www.tandfonline.com/doi/abs/10.1517/14656566.1.5.1053 Page: 6.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.tandfonline.com/doi/abs/10.1517/14656566.1.5.1053 Page: 6.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.tandfonline.com/doi/abs/10.1517/14656566.1.5.1053 Page: 6.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.tandfonline.com/doi/abs/10.1517/14656566.1.5.1053 Page: 6.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894639/	yes [IC50 1.17 uM]

Drug as victim

Target	Modality	Activity	Metabolite
UGT2B15 236	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885136/	major	5-hydroxyrofecoxib 1
UGT1A1 479	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885136/ Page: 4.0	weak	5-hydroxyrofecoxib 1
UGT1A3 470	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885136/ Page: 4.0	weak	5-hydroxyrofecoxib 1
UGT1A4 399	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885136/ Page: 4.0	weak	5-hydroxyrofecoxib 1
UGT1A6 343	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885136/ Page: 4.0	weak	5-hydroxyrofecoxib 1
UGT1A8 323	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885136/ Page: 4.0	weak	5-hydroxyrofecoxib 1
UGT1A9 423	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885136/	yes	5-hydroxyrofecoxib 1
UGT2B7 456	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885136/	yes	5-hydroxyrofecoxib 1

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8887	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8887
ChemicalBook	CB6327130	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6327130
eMolecules	877485	https://www.emolecules.com/cgi-bin/more?vid=877485
MolPort	MolPort-000-883-878	https://www.molport.com/shop/molecule-link/MolPort-000-883-878
MolPort	MolPort-006-817-786	https://www.molport.com/shop/molecule-link/MolPort-006-817-786
Selleck Chemicals	rofecoxib-vioxx	http://www.selleckchem.com/products/rofecoxib-vioxx.html
ZINC	ZINC000000007455	http://zinc15.docking.org/substances/ZINC000000007455

PubMed

Title	Date	PubMed
Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions.	1999 Nov 26	10594344
Rofecoxib.	2000 Jul	11249495
Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs.	2001	11433600
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.	2001	11398914
Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis.	2001	11252687
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.	2001 Apr	11405384
Gastrointestinal damage induced by celecoxib and rofecoxib in rats.	2001 Apr	11330413
Selective COX-2 inhibitors.	2001 Apr	11301685
Cyclo-oxygenase and lipoxygenase pathways in mast cell dependent-neurogenic inflammation induced by electrical stimulation of the rat saphenous nerve.	2001 Apr	11264253
Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.	2001 Apr	11264251
COX-2 inhibitors and the gastrointestinal tract.	2001 Apr	11247885
Rofecoxib (Vioxx): a year in review.	2001 Apr 3	11314439
Rofecoxib as an alternative in aspirin hypersensitivity.	2001 Aug	11488679
Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits.	2001 Aug	11472739
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.	2001 Feb	11160644
FDA refuses companies' request to drop ulcer warning.	2001 Feb 17	11179151
Efficacy of cyclooxygenase-2-specific inhibitors.	2001 Feb 19	11173044
Anti-inflammatory drugs, cyclooxygenases and other factors.	2001 Jan	11336563
Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.	2001 Jan	11144988
Cyclooxygenase inhibitors: any reservations?	2001 Jan-Feb	11478355
Renal effects of COX-2-selective inhibitors.	2001 Jan-Feb	11275626
Gastric preconditioning induced by short ischemia: the role of prostaglandins, nitric oxide and adenosine.	2001 Jul-Aug	11433185
[Selective COX-2 inhibitor. Stomach protection--but not always].	2001 Jun 21	11469005
Cyclooxygenase-2 inhibition and renal function.	2001 Jun 5	11388825
Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial.	2001 Mar	11331167
Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors.	2001 Mar	11318071
[Therapy with preferential and specific COX-2 inhibitors].	2001 Mar	11277028
Is rofecoxib safer than naproxen?	2001 Mar	11252204
Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited.	2001 Mar 15	11266647
[Cyclooxygenase inhibitors].	2001 Mar 17	11307498
Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.	2001 Mar-Apr	11304662
Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications.	2001 Mar-Apr	11304661
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.	2001 May	11478054
Upper gastrointestinal toxicity of rofecoxib and naproxen.	2001 May 3	11336056
[The coxibs, third generation of non-steroidal anti-inflammatory agents].	2001 May-Jun	11508259
LC determination of rofecoxib in bulk and pharmaceutical formulations.	2001 Nov	11516914
COX-1 and COX-2 inhibitors.	2001 Oct	11566042
Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions.	2001 Sep	11570615
Ischemic preconditioning, the most effective gastroprotective intervention: involvement of prostaglandins, nitric oxide, adenosine and sensory nerves.	2001 Sep 21	11567657

Patents

Sample Use Guides

In Vivo Use Guide

Osteoarthritis: the recommended starting dose of rofecoxib (VIOXX) is 12.5 mg once daily. Rheumatoid Arthritis: the recommended dose is 50 mg once daily. Management of Acute Pain and Treatment of Primary Dysmenorrhea: the recommended dose is 50 mg once daily. Acute Treatment of Migraine Attacks with or without aura: the recommended dose is 25 mg once daily.

Route of Administration: Oral

In Vitro Use Guide

THP-1 human macrophages and peripheral blood mononuclear cells were incubated with rofecoxib (at 5, 10, 25 uM). The presence of rofecoxib (at high concentrations) significantly decreased expression of 27-hydroxylase and ABCA1, interfering with normal cholesterol outflow from macrophages.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:55:36 GMT 2025` Edited by `admin` on `Wed Apr 02 07:55:36 GMT 2025`
Record UNII	0QTW8Z7MCR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

M01AH02

Preferred Name

English

ROFECOXIB

Official Name

English

NSC-758705

Code

English

rofecoxib [INN]

Common Name

English

MK-966

Code

English

TRM-201

Code

English

VIOXX

Brand Name

English

ROFECOXIB [MI]

Common Name

English

NSC-720256

Code

English

ROFECOXIB [MART.]

Common Name

English

ROFECOXIB [USAN]

Common Name

English

MK-0966

Code

English

MK0966

Code

English

TRM201

Code

English

ROFECOXIB [VANDF]

Common Name

English

Rofecoxib [WHO-DD]

Common Name

English

4-[4-(Methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone

Systematic Name

English

ROFECOXIB [ORANGE BOOK]

Common Name

English

ROFECOXIB [JAN]

Common Name

English

4-(P-(METHYLSULFONYL)PHENYL)-3-PHENYL-2(5H)-FURANONE

Common Name

English

ROFECOXIB [HSDB]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM01AH02